Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.21 Billion CNY | 4.28% |
| 2022 | 1.16 Billion CNY | 19.9% |
| 2021 | 973.66 Million CNY | 30.2% |
| 2020 | 747.79 Million CNY | -3.41% |
| 2019 | 774.16 Million CNY | 37.61% |
| 2018 | 562.57 Million CNY | 25.98% |
| 2017 | 446.56 Million CNY | 27.68% |
| 2016 | 349.75 Million CNY | 25.8% |
| 2015 | 278.02 Million CNY | 33.52% |
| 2014 | 208.22 Million CNY | 67.82% |
| 2013 | 124.07 Million CNY | 29.08% |
| 2012 | 96.12 Million CNY | 57.18% |
| 2011 | 61.15 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 336.66 Million CNY | 14.01% |
| 2024 Q1 | 324.21 Million CNY | 2.43% |
| 2024 Q2 | 295.3 Million CNY | -8.92% |
| 2023 Q3 | 355.04 Million CNY | 16.87% |
| 2023 Q4 | 316.51 Million CNY | -10.85% |
| 2023 Q1 | 242.06 Million CNY | -9.86% |
| 2023 FY | 1.21 Billion CNY | 4.28% |
| 2023 Q2 | 303.8 Million CNY | 25.5% |
| 2022 Q4 | 268.55 Million CNY | -26.5% |
| 2022 Q3 | 365.36 Million CNY | 24.56% |
| 2022 Q1 | 240.2 Million CNY | -6.57% |
| 2022 FY | 1.16 Billion CNY | 19.9% |
| 2022 Q2 | 293.32 Million CNY | 22.11% |
| 2021 Q3 | 303.89 Million CNY | 26.0% |
| 2021 FY | 973.66 Million CNY | 30.2% |
| 2021 Q1 | 171.48 Million CNY | -26.56% |
| 2021 Q2 | 241.19 Million CNY | 40.65% |
| 2021 Q4 | 257.08 Million CNY | -15.4% |
| 2020 Q3 | 240.33 Million CNY | 32.9% |
| 2020 FY | 747.79 Million CNY | -3.41% |
| 2020 Q1 | 93.11 Million CNY | -60.59% |
| 2020 Q2 | 180.84 Million CNY | 94.21% |
| 2020 Q4 | 233.49 Million CNY | -2.85% |
| 2019 Q3 | 217.65 Million CNY | 9.27% |
| 2019 Q2 | 199.18 Million CNY | 64.52% |
| 2019 FY | 774.16 Million CNY | 37.61% |
| 2019 Q4 | 236.25 Million CNY | 8.55% |
| 2019 Q1 | 121.06 Million CNY | -20.12% |
| 2018 Q3 | 164.37 Million CNY | 9.12% |
| 2018 Q4 | 151.55 Million CNY | -7.8% |
| 2018 FY | 562.57 Million CNY | 25.98% |
| 2018 Q1 | 96 Million CNY | -21.91% |
| 2018 Q2 | 150.63 Million CNY | 56.9% |
| 2017 Q3 | 132.18 Million CNY | 6.58% |
| 2017 FY | 446.56 Million CNY | 27.68% |
| 2017 Q4 | 122.94 Million CNY | -6.99% |
| 2017 Q1 | 67.4 Million CNY | -28.99% |
| 2017 Q2 | 124.02 Million CNY | 84.0% |
| 2016 Q1 | 54.26 Million CNY | -32.58% |
| 2016 Q3 | 107.08 Million CNY | 14.56% |
| 2016 Q4 | 94.92 Million CNY | -11.35% |
| 2016 Q2 | 93.47 Million CNY | 72.26% |
| 2016 FY | 349.75 Million CNY | 25.8% |
| 2015 Q1 | 54.5 Million CNY | 0.0% |
| 2015 Q3 | 88.53 Million CNY | 62.44% |
| 2015 Q4 | 80.48 Million CNY | -9.1% |
| 2015 FY | 278.02 Million CNY | 33.52% |
| 2015 Q2 | 54.5 Million CNY | 0.0% |
| 2014 FY | 208.22 Million CNY | 67.82% |
| 2013 FY | 124.07 Million CNY | 29.08% |
| 2012 FY | 96.12 Million CNY | 57.18% |
| 2011 FY | 61.15 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 273.29 Million CNY | -345.465% |
| Joinn Laboratories(China)Co.,Ltd. | 396.99 Million CNY | -206.665% |
| WuXi AppTec Co., Ltd. | 9.6 Billion CNY | 87.327% |
| Thalys Medical Technology Group Inc. | -158.57 Million CNY | 867.754% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 643.38 Million CNY | -89.225% |
| Chemclin Diagnostics Co., Ltd. | 147.37 Million CNY | -726.091% |